Skip to content
中文产业新闻评分48Chinese source

恒瑞医药与诺和诺德就口服GLP-1/GIP双受体激动剂HRS-1596达成独家许可协议

恒瑞医药与诺和就每周一次口服GLP-1/GIP双受体激动剂HRS-1596达成独家许可协议

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.